InvestorsHub Logo
Followers 34
Posts 2651
Boards Moderated 0
Alias Born 10/28/2013

Re: exwannabe post# 40907

Wednesday, 09/16/2015 9:33:19 PM

Wednesday, September 16, 2015 9:33:19 PM

Post# of 727225
Not entirely true that you can't look backwards. You can, and you must.

I am not blaming the FDA here. I did not say they are in the way. I said that NW should have that information arm under a genetic microsope. They probably do, but if they don't, it seems a tremendous waste of an opportunity.

If you have followed any of the cases of desperate people with GBM online, and listened to the details, and gotten pulled in emotionally... I did. A very sad case that I don't to talk about... but it pulled me in close enough to cut through all the BS and realize the obsurdity that this patient had not had any genetic analysis. You look at every one of the available therapies, except DCVax and one other therapy, and they are all genetic specific. Even DCVax is genetic specific regarding whether or not Temador is a useful adjunct.

There is a ton of knowledge at this point about which drugs/therapies work for which genetics, yet I don't think that is current standard to do a complete genetic analysis on a patient ASAP. Blood tests before tumor removal, and analysis of the tumor afterwards, before deciding which therapies to use. Things are moving that direction... but this is solid known stuff. It makes no sense to spend a couple decades moving that direction. Ridiculous. That I do blame on the FDA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News